Group 1 - The latest round of national drug procurement included 55 types of drugs, with 445 companies participating and 272 companies winning the bid, resulting in a selection rate of nearly 60% [1] - The National Healthcare Security Administration (NHSA) indicated that the competition was more intense than in previous rounds, but measures such as excluding products with a scale below 100 million yuan and setting "anchor prices" helped maintain a high selection rate [1] - The average price difference of selected products has significantly narrowed compared to previous rounds of procurement [1] Group 2 - In the bidding for the flu medication Oseltamivir granules, six companies participated, but the market leader, Yichang Dongyangguang Changjiang Pharmaceutical Co., unexpectedly failed to win a bid [2] - Oseltamivir sales accounted for approximately 67% of Dongyangguang's revenue in the first half of 2025, highlighting the importance of this product to the company [2] - Dongyangguang has long been recognized as the "king of flu medications" in the market [2]